SutroVax Secures $22,000,000 Series A Financing Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=60dae837-6f77-433f-88e9-ba35a559b410
Date
7/24/2015
Company Name
SutroVax
Mailing Address
400 E Jamie Court South San Francisco, CA 94080 USA
Company Description
SutroVax is an independent vaccine platform and development company that was spun-out of Sutro Biopharma. The company will leverage Sutro’s Xpress CF and Xpress CF+ platforms for cell-free protein synthesis and site-specific conjugation to develop novel vaccines for an array of disease targets.
Website
http://www.sutrovax.com
Transaction Type
Venture Equity
Transaction Amount
$22,000,000
Transaction Round
Series A
Proceeds Purposes
SutroVax will use the funds to advance multiple vaccines in its pipeline through pre-clinical proof of concept.
M&A Terms
Venture Investor
Abingworth Management
Venture Investor
Longitude Capital Management
Venture Investor
Roche Venture Fund
Venture Investor
CTI Life Sciences Fund